90673-35-1

Basic information

• Product Name: 3,8-Diazabicyclo[3.2.1]octane dihydrochloride
• Synonyms: 3,8-Diazabicyclo[3.2.1]octane dihydrochloride;(1R,5S)-3,8-diazabicyclo[3.2.1]octane;EOS-62450;3,8-DIAZABICYCLO[3.2.1]OCTANE 2HCL
• CAS NO: 90673-35-1
• Molecular Formula: C6H14Cl2N2
• Molecular Weight: 185.09476
• Mol File: 90673-35-1.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3,8-Diazabicyclo[3.2.1]octane dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3,8-Diazabicyclo[3.2.1]octane dihydrochloride(90673-35-1)
• EPA Substance Registry System: 3,8-Diazabicyclo[3.2.1]octane dihydrochloride(90673-35-1)

Safety Data

• Hazardous Substances Data: 90673-35-1(Hazardous Substances Data)

Usage

General Description

3,8-Diazabicyclo[3.2.1]octane dihydrochloride, also known as DABCO, is a chemical compound commonly used as a catalyst and base in organic synthesis. It has a bicyclic structure and is highly soluble in water, making it useful for a wide range of reactions. DABCO is often employed as a catalyst in the production of polyurethane foams and elastomers, as well as in the synthesis of pharmaceuticals and agrochemicals. It is also used in the formulation of coatings, adhesives, and sealants, and as a stabilizer for pharmaceutical formulations. DABCO dihydrochloride has also shown potential as an anti-HIV agent in medical research. Due to its versatile applications in various industries, DABCO dihydrochloride is a widely utilized compound with significant commercial and scientific value.

Upstream product

• 67571-90-8 3-benzyl-3,8-diazabicyclo[3.2.1]octane 
• 201162-53-0 tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate 
• 96483-83-9 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione 

Downstream Products

• 868406-88-6 3-(5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-trifluoromethoxy-phenyl)-1,1-dimethylsulfonyl-urea 
• 868407-05-0 1-(5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-methyl-phenyl)-tert-butylsulfonyl-urea 
• 868406-79-5 (5-chloro-4-ethoxy-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-phenyl)-urea 
• 868406-70-6 N-[5-chloro-2-{(E)-3-[3-(4-fluoro-benzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-(1-hydroxy-1-methyl-ethyl)-phenyl]acetamide 
• 868406-56-8 1-(5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-methoxyphenyl)-3-methylurea 
• 868406-78-4 N-(5-chloro-4-ethoxy-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-phenyl)-methanesulfonamide 
• 868406-93-3 (E)-(5-chloro-2-{3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-methylphenyl)-urea 
• 868406-65-9 5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxo-propenyl}-4-methoxy-N,N-dimethyl-benzenesulfonamide 
• 868406-75-1 N-(5-chloro-4-ethoxy-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-phenyl)-acetamide 
• 868406-59-1 (E)-(5-chloro-2-{3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-4-methoxyphenyl)-urea 
• 868406-31-9 (E)-(5-chloro-2-{3-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl}phenyl)-carbamic acid tert-butyl ester 
• 868407-12-9 N-(4-bromo-5-chloro-2-{(E)-3-[3-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-8-yl]-3-oxopropenyl}-phenyl)-acetamide 
• 868408-80-4 N-(5-chloro-4-fluoro-2-{(E)-3-[3-(4-fluoro-benzyl)-3,8-diaza-bicyclo[3.2.1]oct-8-yl]-3-oxo-propenyl}-phenyl)-acetamide 
• 868406-52-4 (E)-(5-chloro-2-{3-[8-(4-fluorobenzyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-3-oxopropenyl}-phenyl)-urea 

Relevant articles and documents

THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I): (I) and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.